tradingkey.logo

Australia's Chimeric Therapeutics surges on FDA's 'fast track' tag for neuroendocrine tumour drug

ReutersJun 4, 2025 1:14 AM

Shares of Chimeric Therapeutics CCU.AX rise 12.5% to A$0.005, hitting their highest level since May 29

Stock eyes strongest trading session since May 15, if gains hold

Biotech firm says U.S. Food and Drug Administration has granted "fast track" status to co's CDH17 drug for the treatment of gastroenteropancreatic neuroendocrine tumours

FDA grants "fast track" designation to facilitate the development and expedite the review of drugs to treat serious conditions

Chimeric says "fast track" status will allow co to benefit from more frequent meetings with the FDA for the drug's development plan and potential eligibility for accelerated approval, among others

Stock down 32.5% YTD, including current session's moves

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI